About siga tech - SIGA
SIGA Technologies, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of solutions for medical needs and biothreats. The firm develops therapeutic solutions for lethal pathogens including smallpox, Ebola, dengue, Lassa fever, and other viruses. It offers an orally administered antiviral drug that targets orthopoxviruses under the TPOXX brand. The company was founded by Steven Oliveira on December 28, 1995 and is headquartered in New York, NY.
SIGA At a Glance
SIGA Technologies, Inc.
31 East 62nd Street
New York, New York 10065
| Phone | 1-212-672-9100 | Revenue | 94.57M | |
| Industry | Pharmaceuticals: Major | Net Income | 23.28M | |
| Sector | Health Technology | Employees | 49 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
SIGA Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 18.864 |
| Price to Sales Ratio | 4.643 |
| Price to Book Ratio | 2.201 |
| Price to Cash Flow Ratio | 10.10 |
| Enterprise Value to EBITDA | 11.743 |
| Enterprise Value to Sales | 3.013 |
| Total Debt to Enterprise Value | 0.003 |
SIGA Efficiency
| Revenue/Employee | 1,930,100.041 |
| Income Per Employee | 475,084.551 |
| Receivables Turnover | 28.977 |
| Total Asset Turnover | 0.407 |
SIGA Liquidity
| Current Ratio | 11.83 |
| Quick Ratio | 9.104 |
| Cash Ratio | 8.613 |
SIGA Profitability
| Gross Margin | 68.592 |
| Operating Margin | 25.062 |
| Pretax Margin | 32.125 |
| Net Margin | 24.615 |
| Return on Assets | 10.017 |
| Return on Equity | 11.229 |
| Return on Total Capital | 11.662 |
| Return on Invested Capital | 11.202 |
SIGA Capital Structure
| Total Debt to Total Equity | 0.40 |
| Total Debt to Total Capital | 0.398 |
| Total Debt to Total Assets | 0.361 |
| Long-Term Debt to Equity | 0.101 |
| Long-Term Debt to Total Capital | 0.10 |